CALQUENCE CONFIDENCE
See the latest long-term data in patients with CLL at CALQUENCEhcp . com
Scan the code using your phone to learn more
Indication and Usage CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia ( CLL ) or small lymphocytic lymphoma ( SLL ).
Select Safety Information Serious adverse events , including fatal events , have occurred with CALQUENCE , including serious and opportunistic infections , hemorrhage , cytopenias , second primary malignancies , and atrial fibrillation and flutter . The most common adverse reactions ( ≥ 30 %) of any grade in patients with CLL were anemia , neutropenia , thrombocytopenia , headache , upper respiratory tract infection , and diarrhea .
Please see Brief Summary of full Prescribing Information on adjacent pages . You are encouraged to report negative side effects of prescription drugs to the FDA . Visit www . FDA . gov / medwatch or call 1-800-FDA-1088 .
CALQUENCE is a registered trademark of the AstraZeneca group of companies . © 2020 AstraZeneca . All rights reserved . US-47280 11 / 20